Search results for " transplantation"

showing 10 items of 1513 documents

Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria

2008

Abstract Background Living donor liver transplantation (LDLT) represents an alternative to expand the organ pool for adult patients with hepatocellular carcinoma (HCC) and end-stage liver disease. The purpose of this study was to demonstrate our institutional experience using criteria exceeding those of the University of California San Francisco (UCSF). Patients and Methods Between September 1998 and December 2006, 22 LDLTs were performed for HCC among patients exceeding the UCSF criteria. Results There were 17 men and 5 women of median age 55 years. Multifocal tumors were present in 19 of 22 patients. Tumor grading was: grade I (n = 8), grade II (n = 10), and grade III (n = 4). Microvascul…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentMedizinLiver transplantationGastroenterologyDisease-Free SurvivalLiver diseaseInternal medicineLiving DonorsTumor GradingHumansMedicineIn patientSurvivorsNeoplasm StagingTransplantationbusiness.industryPatient SelectionLiver NeoplasmsCancerMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateHepatocellular carcinomaFemaleSurgerybusinessLiver cancerLiving donor liver transplantationTransplantation Proceedings
researchProduct

Liver transplantation for hepatocellular carcinoma--is there a risk of recurrence caused by intraoperative blood salvage autotransfusion?

2011

<i>Background/Aims:</i> The use of intraoperative blood salvage autotransfusion (IBSA) during surgical approaches may contribute to tumour cell dissemination. Therefore, IBSA should be avoided in cases of malignancy. However, the risks of IBSA might be acceptable in liver transplantation (LT) for selected small hepatocellular carcinoma (HCC). <i>Methods:</i> In total, 136 recipients of LT with histologically proven HCC in the explanted liver were included in this analysis. With regard to tumour recurrence, 40 patients receiving IBSA despite HCC (IBSA group) were compared to 96 patients without IBSA (non-IBSA group). <i>Results:</i> Milan criteria as asses…

AdultMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationMilan criteriaNeoplasm RecurrenceRisk FactorsmedicineCarcinomaHumansAgedSurgical approachIntraoperative blood salvagebusiness.industryOperative Blood SalvageLiver NeoplasmsMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingSurgeryLiver TransplantationHepatocellular carcinomaSurgeryFemaleRadiologyNeoplasm Recurrence LocalbusinessAutotransfusionEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
researchProduct

Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapy

2011

Background & Aims In a previous study, advanced fibrosis was associated with worsening efficacy of antiviral therapy in HCV-transplant patients. We aimed at assessing whether changes in treatment policy, that is starting therapy at lesser stages of fibrosis, have resulted in improved efficacy. Methods Efficacy (rapid, early, end-of-treatment, and sustained viral response (SVR)) and tolerability (peginterferon (pIFN)/ribavirin (RBV) doses, premature discontinuation, dose reductions, anemia, growth factors, transfusions) were compared between two non-contemporaneous cohorts of post-LT naive patients treated with pIFN-RBV: Group 1 (n=44), a historical cohort of patients treated during the peri…

AdultMalemedicine.medical_specialtyCirrhosisAnemiamedicine.medical_treatmentLiver transplantationAntiviral AgentsGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicinemedicineHumansAgedHepatologybusiness.industryRibavirinImmunosuppressionHepatitis CMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTolerabilitychemistryImmunologyFemalebusinessJournal of Hepatology
researchProduct

Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis.

1998

Objective This study compares the results of liver transplantation (LTx) and liver resection (LR) for hepatocellular carcinoma (HCC) to test the widespread hypothesis that LTx is the preferable approach for small HCCs. Summary Background Data With respect to scarcity of donor organs and poor results, LTxs for large HCCs are obsolete. Small HCC transplantations have been reported to result in an excellent survival rate. However, the data of comparative studies are controversial. Methods Patients who were treated curatively by LTx (n = 50) or LR (n = 52) for HCC were included in this retrospective study. Survival and freedom from recurrence were analyzed. Patients were stratified according to…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationGastroenterologyDisease-Free SurvivalResectionText miningInternal medicinemedicineHepatectomyHumansSurvival rateAgedRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateHepatocellular carcinomaSurgeryFemaleNeoplasm Recurrence LocalbusinessResearch Article
researchProduct

Intraoperative assessment of liver organ condition by the procurement surgeon.

2007

Abstract Generally the transplanting surgeon accepts or declines the offer of a marginal organ in view of all available information. Hence, in some cases it is the procurement surgeon who decides about the suitability for potential further liver transplantation. Methods From January 1, 2003 to September 30, 2005, a total of 402 organ procurement operations were performed in our region. Results Due to infrastructural problems in nine cases intraoperative evaluation of liver biopsies was not achievable in time, and the decision to reject the organs was based on the procurement surgeon’s clinical assessment. The main reason for liver rejection was alleged extreme steatosis, (6 of 9) or liver c…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationProcurementMonitoring IntraoperativeMedicineHepatectomyHumansOrgan donationDonor poolAgedTransplantationbusiness.industryMiddle Agedmedicine.diseaseSurgeryTransplantationOrgan procurementLiverTissue and Organ HarvestingSurgeryFemalebusinessClinical evaluationTransplantation proceedings
researchProduct

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.

2015

Background This study aimed to characterize the dynamics of acquisition of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) in CMV donor positive/recipient negative solid organ transplant (SOT) patients receiving long-term antiviral prophylaxis, and to determine whether development of CMI confers protection against CMV disease. Methods A prospective multicenter study was conducted in Spain from September 2009 to September 2012. Whole blood specimens were prospectively collected at 30, 90, 120, 200, and 365 days after SOT, and CMI was determined by enumeration of CMV pp65 and IE-1-specific CD69+/interferon-γ-producing CD8+ and CD4+ T cells by flow cytometry for intracellular cytok…

AdultMalemedicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusDiseaseKaplan-Meier EstimateGastroenterologyAntiviral AgentsPostoperative ComplicationsImmunityInternal medicinemedicineHumansValganciclovirProspective StudiesGanciclovirSurvival analysisAgedPostoperative CareTransplantationImmunity Cellularbusiness.industryIncidence (epidemiology)Organ TransplantationMiddle Agedmedicine.diseaseTransplantationClinical trialInfectious DiseasesTreatment OutcomeImmunologyCytomegalovirus InfectionsFemalebusinessCD8Follow-Up StudiesTransplant infectious disease : an official journal of the Transplantation Society
researchProduct

Non-classic cystic fibrosis associated with D1152HCFTR mutation

2010

Burgel P-R, Fajac I, Hubert D, Grenet D, Stremler N, Roussey M, Siret D, Languepin J, Mely L, Fanton A, Labbe A, Domblides P, Vic P, Dagorne M, Reynaud-Gaubert M, Counil F, Varaigne F, Bienvenu T, Bellis G, Dusser D. Non-classic cystic fibrosis associated with D1152H CFTR mutation. Background: Limited knowledge exists on phenotypes associated with the D1152H cystic fibrosis transmembrane conductance regulator (CFTR) mutation. Methods: Subjects with a D1152H allele in trans with another CFTR mutation were identified using the French Cystic Fibrosis Registry. Phenotypic characteristics were compared with those of pancreatic insufficient (PI) and pancreatic sufficient (PS) cystic fibrosis (CF)…

AdultMalemedicine.medical_specialtyConsensusPancreatic diseaseAdolescentCystic FibrosisGENETICSmedicine.medical_treatmentCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisGastroenterologyMembrane PotentialsCohort StudiesYoung AdultChloridesInterquartile rangeForced Expiratory VolumeInternal medicineCYSTIC_FIBROSISHumansMedicineLung transplantationGenetic Predisposition to DiseaseChildSweatExocrine pancreatic insufficiencyMUTATIONGenetics (clinical)AgedBronchiectasisbiologybusiness.industryHomozygoteMiddle Agedmedicine.diseaseCongenital absence of the vas deferensCystic fibrosis transmembrane conductance regulatorNasal MucosaEndocrinologyAmino Acid SubstitutionChild Preschoolbiology.proteinFemalebusiness
researchProduct

The relevance of anxiety, depression, and coping in patients after liver transplantation

2002

The aim of this study is to investigate the effects of anxiety, depression, and coping on quality of life in patients after liver transplantation. Patients were asked to fill out a postal survey. Two hundred thirty-six of 375 patients (63%) who entered the study returned the questionnaires, and 186 of these patients could be included in the assessment. Anxiety and depression were surveyed using the Hospital Anxiety and Depression Scale; health-related quality of life, using the 36-Item Short-Form Health Survey; and coping strategies, using the Freiburg Questionnaire on Coping With Illness. In terms of physical and mental dimensions of health-related quality of life, psychosocial factors are…

AdultMalemedicine.medical_specialtyCoping (psychology)medicine.medical_treatmentAnxiety depressionAnxietyLiver transplantationHospital Anxiety and Depression ScaleAdaptation PsychologicalmedicineHealth Status IndicatorsHumansIn patientPostoperative PeriodPsychiatryTransplantationHepatologyDepressionbusiness.industrySocial environmentMiddle AgedLiver TransplantationQuality of LifeRegression AnalysisAnxietyFemaleSurgerymedicine.symptombusinessPsychosocialLiver Transplantation
researchProduct

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.

2017

Summary We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous stem-cell transplantation (ASCT). Most common grade ≥3 adverse events were leucopenia (31·4%) and thrombocytopenia (6·8%). The overall response rate (ORR) by investigator-based assessment was 85·4%. Most patients (74%) underwent successful central laboratory-based molecular cytogenetic analysis. No clinically relevant differences in ORR post-induction were seen between patients with or without high-risk cytogenetic abnormalities (86·2% vs. 84·3%)…

AdultMalemedicine.medical_specialtyCyclophosphamideAdolescentPhases of clinical researchGastroenterologyRisk AssessmentTransplantation AutologousDexamethasoneBortezomib03 medical and health sciencesCytogeneticsYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectCyclophosphamideMultiple myelomaDexamethasoneBortezomibbusiness.industryHematologyInduction ChemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationConsolidation ChemotherapyRegimen030220 oncology & carcinogenesisFemalebusinessMultiple Myeloma030215 immunologymedicine.drugStem Cell TransplantationBritish journal of haematology
researchProduct